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Abstract 
Background 
There are few contemporary data on the mortality and morbidity associated with rheumatic 
heart disease (RHD) or information on their predictors. We report the two year follow-up of 
individuals with RHD from 14 low and middle income countries in Africa and Asia.. 
Methods 
Between January 2010 and November 2012, we enrolled 3343 patients from 25 centers in 14 
countries and followed them for two years to assess mortality, congestive heart failure (CHF), 
stroke or transient ischemic attack (TIA), recurrent acute rheumatic fever (ARF), and infective 
endocarditis (IE). 
Results 
Vital status at 24 months was known for 2960 (88.5%) patients. Two thirds were female. 
Although patients were young (median age 28 years, interquartile range 18 to 40), the two year 
case fatality rate was high (500 deaths, 16.9%).  Mortality rate was 116.3/1000 patient-years in 
the first year and 65.4/1000 patient-years in the second year. Median age at death was 28.7 
years. Independent predictors of death were severe valve disease (hazard ratio (HR) 2.36, 95% 
confidence interval (CI) 1.80-3.11), CHF (HR 2.16, 95% CI 1.70-2.72), New York Heart Association 
functional class III/IV (HR 1.67, 95% CI 1.32-2.10), atrial fibrillation (AF) (HR 1.40, 95% CI 1.10-
1.78) and older age (HR 1.02, 95% CI 1.01-1.02 per year increase) at enrolment. Post-primary 
education (HR 0.67, 95% CI 0.54-0.85) and female sex (HR 0.65, 95%CI 0.52-0.80) were 
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associated with lower risk of death. 204 (6.9%) had new CHF (incidence, 38.42/1000 patient-
years), 46 (1.6%) had a stroke or TIA (8.45/1000 patient-years), 19 (0.6%) had ARF (3.49/1000 
patient-years), and 20 (0.7%) had IE (3.65/1000 patient-years). Previous stroke and older age 
were independent predictors of stroke/TIA or systemic embolism. Patients from low and lower-
middle income countries had significantly higher age- and sex-adjusted mortality compared to 
patients from upper-middle income countries. Valve surgery was significantly more common in 
upper-middle income than in lower-middle- or low-income countries. 
Conclusions 
Patients with clinical RHD have high mortality and morbidity despite being young; those from 
low and lower-middle income countries had a poorer prognosis associated with advanced 
disease and low education. Programmes of early detection and treatment of clinical RHD are 
required to improve outcomes. 
Keywords:  rheumatic heart disease, outcomes, mortality, morbidity, developing countries 
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Clinical Perspective 
1) What is new? 
To our knowledge, this is the first prospective multi-center study of mortality and morbidity in 
rheumatic heart disease (RHD) patients from low and middle income countries (LMICs). Clinical 
RHD was associated with high mortality at a median age of 28 years. Complications such as 
congestive heart failure (CHF) and stroke affect a fifth of patients over a two years. Mortality 
was higher in low income, and low-middle income, compared to upper-middle income 
countries. Apart from age and gender, the independent risk factors for mortality (i.e., severe 
valve disease, CHF, dyspnoea, atrial fibrillation, and low education) were modifiable. 
2) What are the clinical implications?  
Clinical guidelines recommend the use of percutaneous or surgical valve interventions for RHD 
with CHF. However, these interventions are not available to the majority of affected patients. 
Strategies to make proven percutaneous and surgical valve interventions more accessible are 
needed to improve the outcome of patients with RHD living in LMICs. Patients with RHD seeking 
tertiary care present with advanced disease, and the markers of severity are the greatest 
determinants of poor outcome. Additional research to identify symptomatic patients with early 
RHD in the whole population (in addition to screening studies of asymptomatic schoolchildren) 
is required in this field. 
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Introduction 
Rheumatic heart disease (RHD) is a major public health problem in low and middle income 
countries (LMICs).1 According to the most recent estimates, there are nearly 33 million people 
with RHD globally, contributing to about 275,000 deaths every year.2 However, there are sparse 
data on RHD demographics, morbidity and mortality and information on factors which affect 
outcomes, from the countries most affected by the disease.3 In most high income countries, 
RHD ceased to be a public health problem several decades ago. Prospective studies describing 
outcomes and progression of RHD from these countries are over 50 years old. Therefore their 
results may not be applicable to current patients in LMICs.4, 5 Moreover, many of these studies 
were performed before the availability of echocardiography for diagnosis, or the use of 
penicillin prophylaxis, drugs for heart failure or surgical and percutaneous valve interventions 
became part of standard care. Therefore, their findings may not be applicable to contemporary 
patient populations. Furthermore, much of the currently available prospective data are from 
small pockets of highly susceptible indigenous groups in New Zealand and Australia.6-8  The 
incidence of acute rheumatic fever (ARF), and RHD-related morbidity and mortality are thought 
to be unusually high in these groups.7 These data may not be generalizable to the majority of 
those with RHD in LMICs because of differences in access to medical care and other socio-
economic factors.  
Data on morbidity and mortality among RHD patients are needed to inform patient 
management, develop healthcare policy and to guide resource allocation for control of RHD in 
LMICs. Suboptimal use of inexpensive interventions such as secondary penicillin prophylaxis 
and oral anticoagulation is well recognized,9, 10 and contemporary data are needed to 
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document the impact of their underuse on important clinical outcomes. In addition, there is 
limited information on the determinants of disease progression and on clinical outcomes in 
contemporary patients with RHD living in LMICs.7 The Global Rheumatic Heart Disease Registry 
(REMEDY) was designed to help fill this knowledge gap.3 We have previously reported the 
baseline characteristics of the 3343 patients recruited from 14 LMICs in REMEDY.9 This report 
describes the major clinical outcomes at two years of follow-up among these patients. 
Methods 
Study design and setting 
The design of the REMEDY study has been published previously.3 Briefly, REMEDY is a 
prospective, multicenter, international, hospital-based registry of patients with symptomatic 
RHD. We enrolled patients with a clinical and echocardiographic diagnosis of RHD, who were 
seen in outpatient clinics, emergency departments or inpatient facilities of 25 participating 
hospitals in 14 countries (12 African countries, Yemen and India).11 We did not include 
asymptomatic patients in whom RHD was detected solely by clinical or echocardiographic 
screening. The study was approved by the institutional review board at each site and the 
subjects gave informed consent. 
 
Follow-up and outcomes 
Clinical, demographic and echocardiographic data were collected at baseline and patients were 
followed up annually for two years. At each visit patients were assessed for occurrence of 
adverse outcomes, use of secondary antibiotic prophylaxis and oral anticoagulation medication, 
and need for valve intervention or surgery. The principal outcomes of interest were death, 
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congestive heart failure (CHF), stroke or transient ischemic attack (TIA), recurrence of acute 
rheumatic fever (ARF), and infective endocarditis (IE). Other outcomes that were monitored 
included non-central nervous system (CNS) systemic embolism, major bleeding, atrial 
fibrillation or flutter (AF), prosthetic heart valve thrombosis, and use of percutaneous or 
surgical valve procedures. 
 
CHF was diagnosed if any two of the following three criteria were present: (i) symptoms 
(dyspnea on exertion or at rest, orthopnea, nocturnal paroxysmal dyspnea, or ankle edema) or 
signs (rales, increased jugular venous pressure or ankle edema) of CHF, (ii) radiologic signs of 
pulmonary congestion, and (iii) treatment with diuretics. Stroke was diagnosed on the basis of 
physician-confirmed sudden onset of neurologic deficit consistent with ischemia/infarction of a 
vascular territory, lasting ≥24 hours, with or without neuroimaging evidence. A similar deficit 
lasting <24 hours was recorded as a transient ischemic attack (TIA). A systemic embolic episode 
was diagnosed clinically in a patient with loss of arterial pulse and/or evidence of end-organ 
ischemia (e.g., ischemic limb pain or gangrene). We used the WHO criteria for diagnosing 
recurrence of ARF11 and the modified Duke’s criteria for diagnosing IE during follow-up.12 We 
determined the severity of valve lesions based on American College of Cardiology/American 
Heart Association recommendations.13 The definitions of all outcome measures have been 
reported previously.3 
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Statistical analysis 
Continuous variables were expressed as means with standard deviations or as medians with 
interquartile ranges as appropriate, and categorical variables as frequencies and percentages. 
Comparisons between categorical variables were assessed for statistical significance using the 
Chi-squared test, and the unpaired t-test was used to determine group differences for 
continuous variables. Linear regression was utilized to explore relationships between variables. 
Test results were adjusted by age and by specifying study centres as clusters.9 
 
We anticipated that mortality among patients with RHD would be about 3.3% per year based 
on a community-based study in India.14 We expected that with 3000 patients followed up for 
two years, we would be able to determine the rates of all the principal outcomes of interest 
(i.e., death, CHF and stroke) individually, with 95% confidence and a precision of ±1%. 
 
The incidence rates of the principal outcomes were calculated as number of events per 1000 
patient-years of follow-up, and countries were stratified by the 2011 World Bank country 
income groups (low income, lower-middle income, and upper-middle income groups).15 We 
used the Stata stptime command to calculate incidence rates, which allowed for variable 
follow-up time for each patient and provided the 95% confidence intervals for the estimate. 
The Stata sts list command was used to determine the risks of the adverse events at interval 
time points. For mortality, CHF, stroke and thromboembolism, we computed Kaplan-Meier 
survival probabilities and determined predictors of death using a Cox multivariable regression 
model. Comparisons between unadjusted events and baseline variables were cross-tabulated 
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and assessed for statistical significance using the Chi-squared test, unpaired t-test  or univariate 
linear regression. 
The variables included in the multivariable model were decided a priori based on prior 
information relating them to prognosis. They were: age, sex, presence of AF, New York Heart 
Association (NYHA) functional class, CHF at enrolment, previous heart valve surgery or 
intervention, a history of stroke or IE, severe disease (severe valve disease of at least one 
affected valve), multivalve involvement and use of secondary penicillin prophylaxis. We also 
determined the association of non-adherence to secondary prophylaxis with the occurrence of 
episodes of ARF, CHF and death. Among patients with an accepted indication for oral 
anticoagulation, we determined the association of adherence to vitamin K antagonists (VKA) 
with the occurrence of stroke/TIA or other systemic embolism, and death. We computed 
hazard ratios (HR) and their 95% confidence intervals (CIs). A p value of 0.05 or less was 
considered statistically significant. All analyses were performed using Stata version 14 
(StataCorp LP, College Station, Texas). 
 
Role of funding source 
The funders of this study had no role in its design, data collection, data analysis, data 
interpretation, writing of the report, or in the decision to submit the paper for publication. The 
corresponding (BMM), lead (LZ and GK), and some other authors (SY, KT, SI, and SR) had full 
access to all the data in the study and all authors had final responsibility for the decision to 
submit for publication.  
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Results 
Between January 2010 and November 2012, 3343 patients were enrolled at 25 participating 
sites. A third of the patients were from low income, 41% from lower-middle and a quarter from 
upper middle income countries. The baseline characteristics of enrolled patients are 
summarized in Table 1.9 Briefly, patients were relatively young (median age 28 years) and 
predominantly female (66.2%). Over a quarter of patients were below the age of 18 years (921 
patients, 27.9%). Mixed mitral and aortic valve disease was the most common pattern of valve 
involvement, except in children <10 years old, in whom isolated mitral regurgitation was the 
predominant lesion. A fifth of the patients were in AF. A substantial proportion had clinical 
signs of CHF (13.2%) or poor functional class (NYHA class III/IV) at presentation (24.2%), 
particularly in low and lower-middle income countries. The use of secondary penicillin 
prophylaxis and oral anticoagulation were generally poor.9  
Vital status at 24 months was known for 2960 (88.5%) patients. At two years 55% of patients 
completed a follow-up visit,20% were interviewed by telephone, and in the remaining, follow-
up information was obtained through relatives or the patient’s physician. Overall, patients were 
followed up for a median of 24 months (interquartile range (IQR), 22.9-26.6), for a total of 
5482.99 person-years of follow-up.  
 
Mortality 
500 patients (16.9%) died (Table 2, Fig. 1). The median age at the time of death was 28.7 (IQR 
17.4-46.6) years. The majority of deaths (n=323, 64.6%) occurred within 12 months of 
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enrolment. The mortality rate was 116.3/1000 patient-years in the first year and 65.4/1000 
patient-years in the second year. There were seven risk factors that were independently 
associated with mortality (Table 4). Severe valve disease (HR 2.36, 95% CI 1.80-3.11), CHF at 
enrolment (HR 2.16, 95% CI 1.70-2.72), AF at enrolment (HR1.40, 95%CI 1.10-1.78), and poor 
NYHA functional class (i.e., III or IV) at presentation (HR 1.67, 95% CI 1.32-2.10) were the 
strongest independent predictors of mortality. There was also a significant increase in mortality 
with increasing age, with adults having a 50% higher risk of death than those less than 18 years 
of age (HR 1.50, 95% CI 1.11-1.95). Education beyond primary school was associated with a 33% 
lower risk of death (HR 0.67, 95% CI 0.54-0.85). Mortality was also lower among female patients 
(HR 0.65, 95% CI 0.52-0.80). 
 
Congestive heart failure and valve procedures 
A third of the patients (1110, 33.4%) had a history of CHF at the time of enrolment. CHF 
occurred in 204 patients (6.9%) over the follow-up period ( 38.42/1000 patient-years;Table 3). 
Most of the variables which were associated with death were also independently associated 
with the occurrence of CHF (Supplementary Table 1). The presence of CHF at baseline conferred 
the greatest hazard for the recurrence of CHF on follow-up (HR 2.43, 95% CI 1.64-3.62).  
Two hundred and twenty three patients (6.7%) underwent valve surgery and 57 (1.7%) 
underwent percutaneous intervention. 
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Stroke and thromboembolism 
Overall, 46 (1.7%) patients had a stroke or TIA at the end of two years (8.45 per 1000 patient-
years; Table 3) and three patients had non-CNS systemic embolism. Patients who were in AF at 
enrolment were twice as likely to have a stroke as those who were in sinus rhythm (2.4% vs. 
1.2%, p=0.04). Stroke also occurred more commonly among patients with prosthetic heart 
valves than in those with native valves (2.6% vs. 1.1%, p=0.01). However, after adjustment for 
other variables, previous stroke (HR 2.71, 95% CI 1.18-6.39), and older age remained the only 
significant predictors of stroke, TIA or systemic embolism. Prosthetic heart valve thrombosis 
occurred in 9 of 547 patients (1.64%) with mechanical valves (There were 588 patients with 
prosthetic valves, 547 of whom had mechanical valves).  
 
At baseline, there were 1362 (40.7%) patients with indications for oral anticoagulation.9 VKAs 
were prescribed in 69.5% (946) of such patients.  VKA use was high in patients with mechanical 
heart valves (91.6%) and AF (68.6%), but low in those with mitral stenosis in sinus rhythm 
(20.3%) with other markers of high embolic risk (such as dilated left atrium or left atrial 
thrombus). Among patients prescribed VKAs, just over a quarter (27.4%) had an International 
Normalised Ratio (INR) in therapeutic range.  
 
Among patients with native valves and AF or those with mitral stenosis and concomitant high 
risk features, the likelihood of suffering a stroke was lower among patients who had an INR in 
the therapeutic range (i.e., 2-3) at baseline (1.4% vs. 4.3%, p=0.031). For patients with 
mechanical valves (n=547), the risk of stroke was not statistically different between those with 
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INR in therapeutic range or otherwise (3.0 vs. 3.6%, p=0.69). There were 23 major bleeding 
events (0.8%) in all. The incidence of bleeding did not differ significantly by INR at baseline. 
 
Acute rheumatic fever, infective endocarditis and secondary prophylaxis 
Nineteen patients (0.6%) had ARF, and 20 (0.7%) had IE. At enrollment, just over half the 
patients (1761, 54.8%) were on secondary prophylaxis and of these  78% were adherent to 
therapy (i.e., had received ≥80% of the prescribed number of doses in the preceding 12 
months).9 Patients who were prescribed secondary prophylaxis were less likely to have ARF, 
new onset of CHF or die at two years (16.2% vs. 20.7% p=0.001). However, this association did 
not remain statistically significant after adjustment for other prognostic variables. 
The incidence rates of all morbid events are summarized in Table 3. 
 
Country income group 
Patients from upper middle income countries were older, and more often had a history of 
complications due to valve disease (such as stroke or IE), or were in CHF at baseline (Table 1).9 
A larger proportion of patients from upper middle income countries (UMIC) had valve surgery 
or intervention prior to entry into the study. Consequently, the risk of valve-related and 
anticoagulation related problems (such as stroke) were significantly higher among these 
patients. However, they were significantly less likely to die at the end of two years compared to 
patients from low (LIC) and lower-middle income (LMIC) countries (12.7% UMIC, 14.2% LMIC 
and 18.0% (LIC), respectively; p=0.001) (Fig. 2). The hazard for mortality remained higher for 
low-income (HR 1.95, 95% CI 1.51-2.50) and low-middle income countries (HR 1.51, 95% CI 
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1.17-1.92), when compared to upper middle income countries, after adjustment for patient age 
and sex. Adjustment for all other prognostic variables resulted in attenuation of risk for low 
income countries (HR 1.53, 95% CI 1.12-2.14), and low-middle income countries (HR 1.34, 95% 
CI 1.02-1.87). 
 
Discussion 
In this contemporary registry, the rates of death, CHF and stroke are high among patients with 
clinical RHD living in LMICs despite their relatively young age (mean 28 years). Nearly a fifth of 
patients developed one of these complications over two years. This was largely attributable to 
advanced disease at the time of presentation. Mortality was significantly higher among patients 
living in low income countries and among the less educated. The use of secondary antibiotic 
prophylaxis was suboptimal. Oral anticoagulation was underutilized and the quality of oral 
anticoagulation was poor, contributing to an increased risk of stroke. These indicate that 
patients with RHD are managed suboptimally despite the availability of simple and effective 
preventive and management strategies. 
 
There are few contemporary prospective studies reporting on mortality among patients with 
echocardiographically confirmed RHD. In a small community-based cohort of 257 patients with 
RHD who were followed up for 12 years, Kumar and colleagues reported a death rate of 
32.5/1000 patient-years. In a report from a register from the Northern Territory of Australia, 
Lawrence and colleagues showed a survival of 96.1% at 5 years, and 88.4% at 10 years.7 The 
mortality rates reported in these studies are those of unselected patients with ARF and RHD 
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recruited from the community and not surprisingly are substantially lower than our estimates. 
Moreover, nearly all patients were on secondary prophylaxis and had access to high quality 
care through outreach services by expert clinicians.7 By contrast, Gunther and colleagues 
reported a very high mortality rate of 125·3 per 1000 person-years in a small cohort of 47 
patients in a community from Ethiopia, but there was an excessively high loss to follow-up rate 
of 44%.16 
 
Several of the factors which we found to be strongly associated with mortality and other major 
adverse outcomes are potentially amenable to intervention. The majority of our patients had 
moderate to severe disease and nearly a third were in NYHA class III/IV at enrolment,9 and the 
severity of valve disease was the strongest predictor of mortality. While most of these patients 
were likely to require intervention, only 10.3 % (n=175) of those with severe valve disease had 
surgery or percutaneous intervention. In a study of newly diagnosed RHD with a similar profile, 
seen at a well-equipped tertiary care center in South Africa, 22% of patients underwent surgery 
at 30 months of follow-up.17 Timely surgery or percutaneous intervention may improve 
outcomes in patients with severe disease.13, 18 However, facilities for cardiac surgery are scarce 
in poor countries and waiting periods are long.19, 20 Gaps in the use of effective therapies may 
be due to difficulties in access to care, and may explain some of the observed difference in 
mortality between middle income and low income countries (Fig. 2). Strategies to provide high-
quality tertiary care for patients with RHD have been proposed in Africa. 21 
 
18 
 
Despite a substantial proportion of patients being in AF, oral anticoagulation was used in only 
70% of these individuals. Even among patients with mechanical valves, about 9% of patients 
were not on any oral anticoagulation. Among those on VKAs, INR monitoring was infrequent 
and less than a third of patients were in therapeutic range. Predictably, patients with INRs out 
of therapeutic range had a 3-fold higher risk of stroke. Underuse of oral anticoagulation is 
widespread,22 but the level of INR  control is poorer in developing countries. In a worldwide 
registry of AF, the time in therapeutic range for patients from Africa, China and India was below 
40%.23 This may be due to poor awareness by both physicians and patients on their importance, 
poor patient education and limited access to INR testing.24, 25 Strategies targeting these factors 
are needed to improve clinical outcomes with oral anticoagulation. While self-monitoring using 
point-of-care devices may be theoretically appealing, they are currently not affordable for the 
majority of patients in Africa and Asia.26, 27 Moreover it is unknown if patients in LMICs can 
effectively self-monitor and adjust their VKA doses. Perhaps novel approaches need to be 
tested, such as the recruitment of educated and motivated individuals from the community 
(e.g., local school teachers), and may be useful surrogate healthcare providers to perform home 
monitoring.14 While newer oral anticoagulants overcome the need for monitoring, their efficacy 
and safety in RHD is unknown and they are at present unaffordable to the majority of patients 
living in poor countries. However, it is possible that in future these drugs may become more 
affordable and widely used (as has happened with antiretroviral therapy for HIV), and therefore 
trials evaluating these agents in RHD are needed.9, 28 
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Although there was a significant association of non-use of secondary prophylaxis with the 
occurrence of ARF, CHF or death, this was attenuated after adjustment for other prognostic 
variables. The effect of secondary prophylaxis on the occurrence of CHF or death is likely to be 
greatest among patients in the early stages of disease. Patients in poor countries are likely to 
have suffered substantial valve damage from multiple, unrecognized episodes of ARF before 
they first come to clinical attention, at which point the hemodynamic consequences of severe 
valve disease may be the overwhelming determinants of prognosis.29 A similar lack of impact of 
secondary prophylaxis on mortality was observed in the Australian Northern Territory register 
which relied on clinical diagnosis of RHD at the point of entry.7 These findings highlight the 
need for studying the efficacy of earlier institution of secondary prophylaxis in patients 
detected through screening programmes,30, 31 combined with approaches to prevent the first 
episode of ARF.29 In patients with advanced disease, given its documented effect of reducing 
recurrences of ARF, secondary prophylaxis should continue to be administered in addition to 
definitive therapy for valve disease.32 
 
Finally, education beyond primary school was associated with a significant reduction in 
mortality. Patient education is an indicator of socioeconomic status in resource-poor countries. 
A multi-national retrospective study of African patients with rheumatic heart disease showed 
that the ratio of patients with severe disease to any RHD valvular lesion was higher in countries 
with the lowest gross domestic product.33 This observation is consistent with the mortality 
gradient observed with respect to the country income group in this study. These findings point 
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to the inextricable link between socioeconomic development and RHD, and emphasize the 
need for overall societal development as a key prerequisite for RHD control.34 
 
Our study has several strengths. First, it is the largest prospective study of patients with RHD in 
LMICs allowing for precise estimates of patient-important clinical outcomes. Second, the 
diagnosis of RHD was confirmed by echocardiography, and disease severity and clinical 
outcomes were measured using pre-specified, objective criteria, thereby reducing bias. Third, 
because we collected data from various countries in different stages of economic development, 
we were able to explore some of the socioeconomic factors that influence outcomes. The most 
important limitation of this study is that despite extensive efforts to track patients, 11.7% of 
our patients were lost to follow-up. Though this proportion was lower than initially projected 
(20%), it reflects the challenging and resource constrained settings in which the study was 
conducted.16, 35 Moreover, significantly greater proportions of those lost to follow-up had 
severe disease, were in CHF or worse functional class at enrolment, or were less educated 
(Supplementary Table 2) and so our data may be an underestimate of the poor prognosis in this 
condition. Finally, this is a hospital-based registry of symptomatic patients and so our results 
cannot be extrapolated to unselected patients with the disease in the community. Whether 
those who are asymptomatic when they are initially encountered will have a similar disease 
trajectory is not known.36  
 
Conclusion: Clinical RHD is associated with high morbidity and mortality in young adults. Better 
access to high-quality tertiary care services, and optimizing the use of proven interventions 
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such as secondary antibiotic prophylaxis and oral anticoagulation are likely to improve 
outcomes. Given the scarcity of high quality data (from large international registries and 
randomized trials), more research is needed to devise effective ways of preventing ARF, 
detecting early RHD, improving access to essential care, and preventing disease progression.  
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Figure legends 
Figure 1: Kaplan-Meier estimates of time to death (in months) in the overall group. 
Figure 2: Risk of age and sex-adjusted mortality by country-income group.  
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Figure 1: Kaplan-Meier estimates of time to death (in months) in the overall group. 
 
Figure 2: Risk of age and sex-adjusted mortality by country-income group.  
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Mortality was higher in low income countries (HR 1.95, 95% CI 1.51-2.50, p<0.0001) and low-
middle income countries (HR 1.51, 95% CI 1.17-1.92, p=0.001).   
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Table 1: Baseline characteristics of the 3343 children and adults with rheumatic heart disease 
by country income group 
 Low income 
countries 
N=1110  
Lower middle 
income 
countries 
N=1370  
Upper middle 
income 
countries 
N=863  
p value  
Age, median 
(IQR) 
24 (15-34) 28 (18-38) 39 (22-52) 0.51 
Women, n (%) 728 (65. 8) 867 (63.0) 616 (71.3) 0.33 
Schooling below 
or at primary 
school, n (%) 
312 (44.7) 632 (62.3) 242 (35) 0.23 
Atrial fibrillation, 
n (%) 
163 (18.2) 241 (22.6) 182 (27.5) <0.0001 
Severe disease, 
n (%)* 
682 (61.4) 684 (49.9) 343 (39.8) <0.001 
Multi-valve 
disease, n (%) 
719 (64.8) 825 (60.2) 470 (54.7) <0.001 
Congestive heart 
failure at 
enrolment, n (%) 
173 (15.9) 165 (12.2) 102 (11.9) 0.010 
New York Heart 306 (27.6) 384 (29.1) 119 (13.9) 0.24 
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Association 
functional class 
III/IV, n (%) 
Prior infective 
endocarditis, n 
(%) 
25 (2.3) 59 (4.4) 49 (5.7) <0.001 
Prior stroke or 
systemic 
embolism, n (%) 
58 (5.2) 52 (3.8) 125 (14.5) <0.001 
Secondary 
prophylaxis, n 
(%) 
716 (69.8) 794 (59.7) 251 (29.3) <0.001 
 
 IQR, inter-quartile range; *Severe disease includes all patients with severe disease involving at 
least one valve.  
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Table 2:  Clinical outcomes at two years of follow-up in 2960 children and adults with rheumatic 
heart disease 
 Low income 
countries 
(N=964) 
Lower middle 
income countries 
(N=1158) 
Upper middle 
income countries 
(N=838) 
p 
  
Death, n (%) 200 (20.8) 195 (16.8) 105 (12.5) <0.001 
Congestive heart failure, n 
(%) 
87 (9.0) 66 (5.7) 51 (6.1) 0.006 
Stroke or transient 
ischaemic attack, n (%) 
14 (1.5) 12 (1.0) 20 (2.4) 0.053 
Recurrence of acute 
rheumatic fever, n (%) 
4 (0.4) 11 (1.0) 4 (0.5) 0.244 
Infective endocarditis, n (%) 1 (0.1) 13 (1.1) 6 (0.7) 0.18 
Atrial fibrillation  28 (2.9) 14 (1.2) 14 (1.7) 0.013 
Prosthetic valve thrombosis  0 (0) 2 (0.1) 7 (1.0) 0.003 
Surgery 30 (3.1) 84 (7.3) 109 (13.0) <0.001 
Death, congestive heart 
failure or acute rheumatic 
fever, n (%) 
251 (26.0) 228 (19.7) 143 (17.1) <0.001 
Death, stroke, systemic 
embolism or major 
bleeding, n (%) 
209 (21.7) 203 (17.5) 129 (15.4) 0.002 
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Table 3: Incidence of morbid outcomes in in 2960 children and adults with rheumatic heart 
disease followed up over two years 
 
Outcome Number of events 
over 27 months 
Patient-years Incidence 
rate per 1000 
95% Confidence 
interval 
Congestive cardiac 
failure 
204 5309.1 38.42 33.50-44.10 
Stroke or transient 
ischaemic attack 
46 5440.8 8.45 6.33-11.29 
Acute rheumatic 
fever 
19 5444.9 3.49 2.23- 5.47 
Infective 
endocarditis 
20 5473.8 3.65 2.36-5.66 
Atrial fibrillation 56 5431.1 10. 3 7.94-13.40 
Major bleeding 23 5455.5 3.51 2.80-6.34 
Prosthetic valve 
thrombosis 
9 5478.9 1.64 0.85-3.16 
Valvuloplasty 57 5403.8 8.83 8.14-13.67 
Surgery 223 5187.7 42.99 37.70-49.01 
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Table 4: Predictors of mortality in in 2960 children and adults with rheumatic heart disease 
followed up over two years 
*Hazard ratio was 1.16 (1.11-1.25) when age was categorized as <18, and 10 year increments 
thereafter. 
†Severe disease refers to patients with severe disease involving at least one valve. 
Baseline variable Hazard ratio 95% Confidence 
interval 
p value  
Age* 1.02 1.01 - 1.02 <0.0001 
Female sex 0.65 0.52 - 0.80 <0.0001 
Education beyond primary school 0.67 0.54 - 0.85 0.001 
Atrial fibrillation 1.40 1.10 - 1.78 0.008 
Severe disease† 2.36 1.80 - 3.11 <0.01 
Multi-valve disease 0.97 0.75 - 1.25 0.852 
Congestive heart failure at enrolment 2.16 1. - 2.72 <0.001 
New York Heart Association functional 
class III/IV 
1.67 1. 32 - 2.10 <0.001 
Prior valve intervention or surgery 0.78 0. 57 - 1.07 0.14 
Prior infective endocarditis 1.30 0.84 – 2.14 0.22 
Prior stroke 1.19 0. 78 - 1.77 0.39 
On secondary antibiotic prophylaxis at 
enrolment 
0.86 0. 70 - 1.09 0.17 
